AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03527355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT
Description: Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
Study NCT01653015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Attenuated Influenza Vaccine
Description: Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
Study NCT03527355 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi-DT
Description: Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
Study NCT03527355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluQuadri™
Description: Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding.
Study NCT03527355 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FluQuadri™
Description: Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding.
Study NCT03527355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride isotonic solution
Description: Manufacture: Euro-Med Inc. Dose: 0.5 mL
Study NCT04376554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days
Study NCT04376554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin-clavulanate
Description: amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
Study NCT00421434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
Study NCT00421434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
Study NCT00421434 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
Study NCT00421434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
Study NCT00421434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
Study NCT00788957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT02879617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study NCT01055275 — intervention group
Intervention type: DEVICE
Intervention: Implantation with a Cook Iliac Branch Graft
Description: Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
Study NCT04616638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training for Empowerment (RT-POWER)
Description: The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
Study NCT04616638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A traditional RT intervention
Description: The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
Study NCT02288845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Study NCT01987739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg almorexant
Study NCT02706860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT02578667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gorbly Compression Device
Description: The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
Study NCT01987739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant
Study NCT00719381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
Study NCT03231839 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caloric restriction
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
Study NCT03231839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no red meat
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
Study NCT03231839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increased fiber intake
Description: After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
Study NCT03231254 — intervention group
Intervention type: DEVICE
Intervention: Remotely Controlled Mandibular Positioner (RCMP)
Description: RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
Study NCT03105609 — intervention group
Intervention type: DEVICE
Intervention: Hyperspectral imaging
Description: Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
Study NCT04641429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Description: Participants in the experimental group receive 12-week group-based Qigong exercise training.
Study NCT04641429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Participants in the control group receive 12-week group-based stretching exercise training.
Study NCT00343980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice a day.
Study NCT00343980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study NCT00343980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: Tablets, 4 mg/day.
Study NCT00343980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 4 mg/day.
Study NCT03731754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Closure
Description: Primary closure discontinuously the perineal wound of APR
Study NCT03731754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cross closure
Description: Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
Study NCT00495261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-enhanced cognitive behavioural therapy (MCBT)
Description: a variation of cognitive behavioural therapy (CBT)
Study NCT04152629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
Study NCT01987739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant
Study NCT01987739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem
Study NCT04152629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
Study NCT04272775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study NCT00495261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation-enhanced cognitive behavioural therapy (RCBT)
Description: a variation of cognitive behavioural therapy (CBT)
Study NCT03847389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clobetasol propionate 0.05% Topical Oil
Description: thin film application of the oil twice daily
Study NCT02131155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT02131155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily
Study NCT04557930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopewell Hospitalist Video Game
Description: Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
Study NCT04174248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCSMS App
Description: Breast Cancer Using a Self-Management Support mHealth Application
Study NCT01019044 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal mucosa biopsy
Description: Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
Study NCT00529490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic lactate
Description: Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
Study NCT00529490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
Study NCT01221948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Rechargeable Deep Brain Stimulation System
Study NCT03825783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L201
Description: CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Study NCT00529750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRBESARTAN
Description: Tablets
Study NCT00529750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Tablets
Study NCT00079001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT00079001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT00079001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: androgen deprivation therapy
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
Study NCT00079001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
Study NCT00079001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
Study NCT00079001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
Study NCT00079001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium supplement
Description: Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Study NCT00079001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Study NCT00079001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Study NCT00079001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Study NCT01595568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
Study NCT03125005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow Universal Pulse Oximeter Sensor
Study NCT03835325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cogmax®
Description: Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
Study NCT02280239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
Study NCT01987739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem
Study NCT02280239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
Study NCT02591134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Nutritive Sweetened Beverages
Description: Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
Study NCT02591134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
Study NCT00522626 — intervention group
Intervention type: DEVICE
Intervention: Maternal fetal monitoring
Description: Simultaneous monitoring of maternal and fetal physiology
Study NCT03337646 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lisdexamfetamine Dimesylate
Description: Medication to treat ADHD
Study NCT03829124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg
Study NCT03829124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg
Study NCT03829124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
Study NCT02239380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study.
Study NCT02680548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Study NCT02680548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine hydrochloride injectable suspension USP
Study NCT02680548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg/cc methylprednisolone acetate injectable suspension USP
Study NCT04534257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION Sirolimus DCB
Description: Suitable lesions will be treated with SELUTION Sirolimus DCB
Study NCT02686034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore-S
Description: At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
Study NCT02686034 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore-S Sham
Description: At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
Study NCT00606190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde brain perfusion
Description: observational
Study NCT00606190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade brain perfusion
Description: observational
Study NCT02636270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex
Description: Treat PAPP-A2 deficient patients with Increlex
Study NCT04849286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution
Study NCT03323879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR/HDR
Description: Focal LDR to dominant lesion with whole gland 19 Gy HDR
Study NCT02613104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotion recognition modification - sad>happy
Description: Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
Study NCT02613104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: emotion recognition modification - sad>happy control
Description: Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.